Cancer
The RRs of cancer (9 trials of 5 HIF-PHIs, containing 5189 participants[26, 31-36, 39, 40]) with HIF-PHIs in DD patients were no statistical increases compared with ESAs: Roxadustat (RR: 0.25, 95% CI: 0.03-2.24, p=0.22, I2=0%), Enarodustat (RR: 1.98, 95% CI: 0.18-21.40, p=0.57, I2=0%), Daprodustat (RR: 0.86, 95% CI: 0.60-1.24, p=0.42, I2=0%), Vadadustat (RR: 0.77, 95% CI: 0.30-2.03, p=0.60, I2=0%) and Molidustat (RR: 1.86, 95% CI: 0.64-5.42, p=0.25, I2=0%) (Figure 4).